Cytodyn Inc (CYDY)

[finesand]

Compilation Update + Catalyst Calendar

Update Log,

2018-08-17 - August 2018 Presentation Update (WIP)

2018-06-23 - Evaluation (needs update soon),

2018-07-29 - 2018 10-K Brief Overview,

2018-07-19 - Presentation at Singular Summer Solstice 2018 Conference,

2018-07-17 - Investment Community Conference Call,

2018-07-22 - Comparison HIV-1 Anti-infective antibodies,

2018-06-30 - Pro 140 Related Publications,

2018-06-26 - Pro 140 Metastatic Cancer Suppression,

2018-06-18 - The return of PRO 140, a CCR5-directed mAb,

2018-06-14 - Pro 140 Covering Scientists,

2018-06-23 - Insider Ownership,

2018-06-22 - PRO 140 SC Combo about to arrive,

2018-02-20 - Pro 140 Phase 2b/3 Pivotal PE Achieved,

2018-04-10 - CEO Letter to Investor


Calendar from August 2018 Presentation, PRs & Notes

Pro 140 Important Milestones for HIV 2018/2019
- DONE: CD02 Pivotal Phase 3 Endpoint Achieved (ASM Microbe late breaker) (Source: CYDY)
- DONE: Full CD02 Trial Data Disclosure via 7/16 PR.
- DONE: Medical Conference Presentations (CROI and ASM Microbe) (Source: CYDY)
- DONE: Publication of Monotherapy (Phase 2b, CD01) (Source: CYDY)
- DONE: 150pt 24weeks 350mg safety data, 89 CD03 pts from 2017-10-17 completed on 2018-04-03 (7/17 CC + Deduction)
- DONE: CD03 Enrollment Completed 303pt: 350mg 48 weeks complete 2019-06-18 2Q19-3Q19 (7/17 CC + Deduction)
- CONT: CD03 Continuous Enrollment for 525mg (new) and 700mg (new) (7/17 CC + Deduction)
- 2H18: Publication Studies – CD02 Combo Primary Endpoint Study (Source: CYDY 7/19 CC)
- 2018: BLA Submission (2/3 Sections: Clinical + Non-Clinical, ex CMC) (Source: CYDY)
- 2018: (File for) HIV Breakthrough Therapy Designation (BTD) (Source: CYDY 7/19 CC)
- 2018: Exploring Partnership with small & larget Pharma (Source: CYDY)
- 1Q19: BLA Submission (Last Section: CMC) (Source: CYDY)
- 1Q19: Mono CD03 Phase 3 Pivotal Trial for Label Expansion Approval (Classification, not Trial) (Source: CYDY)

Pro 140 Milestones - Cancer & Other Indications
- DONE: Orphan Drug Designation for GvHD (ODD) granted by FDA (Source: CYDY)
- DONE: Published GvHD Preclinical Studies (Source: CYDY)
- DONE: Colon Cancer Animal Study Statistical Significant Results (8/15 CYDY PR)
- 3Q18: Complete Acquisition of ProstaGene (All share deal for Pestell&Co, how much?) (Source: CYDY)
- 4Q18: Colon Cancer Animal Study (Full Results, Paper?) (Source: CYDY)
- 2018: (File) IND Submission for Colon Cancer (Phase 2) (Source: CYDY)
- 2018: (File) IND Submission for MS (Phase 2) (Source: CYDY)
- 2018: GvHD data review of 10(?) additional pts by iDMC soon (CYDY 7/19 CC)???
- 1H19: File IND for Breast Cancer - Inhibition of Metastasis (Source: CYDY)


Expected Other Events
- Paulson CYDY Investor Meeting in Redwood City w/ Pourhassan and Pestell on 8/21 or 8/22 (Rumor)
- ~$70M financing of next 12 Month for HIV-1 and GvHD ex Cancer: Offering, Partnership, ..
- 150 pts safety data for Combo BLA (CYDY 7/17 CC)
- CD03 Mono prelim data 2Q19?
- Combo BLA acceptance 1H19
- Combo BLA approval 2H19
- Mono sBLA filing 2H19, acceptance 1H20?

+++

Latest PR & Social Media

- 8/10 EmergingGrowth.com NewsWire Bullish Stock Article
-- Probably Sponsored by CYDY

- 8/13 CYDY PR: Klump BOD
-- Material Bullish

- 8/15 CYDY: Preclinical Colon Carcinoma Success w/ Mice
-- Material Bullish

- 8/16 SA Bullish Stock Article

- 8/17 NetworkNewsWire Bullish Stock Report
-- Sponsored by CYDY
-- Also covered by MarketWatch

+++